Tadalafil therapy for pulmonary arterial hypertension - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Jun 9;119(22):2894-903.
doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26.
Bruce H Brundage, Hossein A Ghofrani, Ronald J Oudiz, Gerald Simonneau, Zeenat Safdar, Shelley Shapiro, R James White, Melanie Chan, Anthony Beardsworth, Lyn Frumkin, Robyn J Barst; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Collaborators, Affiliations
- PMID: 19470885
- DOI: 10.1161/CIRCULATIONAHA.108.839274
Randomized Controlled Trial
Tadalafil therapy for pulmonary arterial hypertension
Nazzareno Galiè et al. Circulation. 2009.
Erratum in
- Circulation. 2011 Sep 6;124(10):e279. Dosage error in article text
Abstract
Background: Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.
Methods and results: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. The primary end point was the change from baseline to week 16 in the distance walked in 6 minutes. Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01). Overall, the mean placebo-corrected treatment effect was 33 m (95% confidence interval, 15 to 50 m). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (P=0.041), incidence of clinical worsening (68% relative risk reduction; P=0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing.
Conclusions: In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.
Trial registration: ClinicalTrials.gov NCT00125918.
Similar articles
- Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Barst RJ, et al. J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009. Epub 2011 Jan 21. J Heart Lung Transplant. 2011. PMID: 21256048 Clinical Trial. - Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group. Oudiz RJ, et al. J Am Coll Cardiol. 2012 Aug 21;60(8):768-74. doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18. J Am Coll Cardiol. 2012. PMID: 22818063 Clinical Trial. - Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Rubin LJ, et al. N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212. N Engl J Med. 2002. PMID: 11907289 Clinical Trial. - Tadalafil: in pulmonary arterial hypertension.
Croxtall JD, Lyseng-Williamson KA. Croxtall JD, et al. Drugs. 2010 Mar 5;70(4):479-88. doi: 10.2165/11204580-000000000-00000. Drugs. 2010. PMID: 20205489 Review. - Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA, Poon H. Arif SA, et al. Clin Ther. 2011 Aug;33(8):993-1004. doi: 10.1016/j.clinthera.2011.06.008. Epub 2011 Jul 16. Clin Ther. 2011. PMID: 21762988 Review.
Cited by
- Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.
Tsai J, Malik S, Tjen-A-Looi SC. Tsai J, et al. Life (Basel). 2024 Oct 4;14(10):1265. doi: 10.3390/life14101265. Life (Basel). 2024. PMID: 39459565 Free PMC article. Review. - Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.
Corboz MR, Nguyen TL, Stautberg A, Cipolla D, Perkins WR, Chapman RW. Corboz MR, et al. J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):241-283. doi: 10.1089/jamp.2024.0016. J Aerosol Med Pulm Drug Deliv. 2024. PMID: 39388691 Review. - Diagnosis and Management of Pulmonary Hypertension: New Insights.
Ntiloudi D, Kasinos N, Kalesi A, Vagenakis G, Theodosis-Georgilas A, Rammos S. Ntiloudi D, et al. Diagnostics (Basel). 2024 Sep 16;14(18):2052. doi: 10.3390/diagnostics14182052. Diagnostics (Basel). 2024. PMID: 39335731 Free PMC article. Review. - Treatment algorithm for pulmonary arterial hypertension.
Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, McLaughlin VV, Sitbon O. Chin KM, et al. Eur Respir J. 2024 Oct 31;64(4):2401325. doi: 10.1183/13993003.01325-2024. Print 2024 Oct. Eur Respir J. 2024. PMID: 39209476 Free PMC article. Review. - Mechanisms and treatment of pulmonary arterial hypertension.
Ghofrani HA, Gomberg-Maitland M, Zhao L, Grimminger F. Ghofrani HA, et al. Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01064-4. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 39112561 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous